Annexin A5 as a potential marker in tumors

Clinica Chimica Acta

Volumn 427, Issue , 2014, Pages 42-48

  Peng, Boya ^a   Guo, Chunmei ^a   Guan, Hongwei ^a   Liu, Shuqing ^a   Sun, Ming Zhong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A5; Drug resistance; Malignancy; Tumor

Indexed keywords

BERBERINE; CALVASCULIN; CISPLATIN; FLUOROURACIL; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LIPOCORTIN 5; METASTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN SHC; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLADDER SURGERY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; FIBROSARCOMA; GLIOMA; HUMAN; IC 50; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TUMOR INVASION; TUMOR PROMOTION; TUMOR THROMBUS; TUMOR VASCULARIZATION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; METABOLISM; NEOPLASMS;

ANNEXIN A5; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886256880     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.09.048     Document Type: Review

References (68)

1. Moss S.E., Morgan R.O. The annexins. Genome Biol 2004, 5(4):219.
2. Laohavisit A., Davies J.M. Multifunctional annexins. Plant Sci 2009, 177:532-539.
3. Haigler H.T., Fitch J.M., Jones J.M., et al. Two lipocortin-like proteins, endonexin II and anchorin C II, may be alternate splices of the same gene. Trends Biochem Sci 1989, 14:48-50.
4. Smith P.D., Moss S.E. Structural evolution of the annexin supergene family. Trends Genet 1994, 10:241-246.
5. Fatimathas L., Moss S.E. Annexins as disease modifiers. Histol Histopathol 2010, 25:527-532.
6. Liemann S., Huber R. Three-dimensional structure of annexins. Cell Mol Life Sci 1997, 53:516-521.
7. Mussunoor S., Murray G.I. The role of annexins in tumour development and progression. J Pathol 2008, 216:131-140.
8. Laohavisit A., Davies J.M. Annexins. New Phytol 2011, 189:40-53.
9. 2+ signalling to membrane dynamics. Mol Cell Biol 2005, 6:449-461.
10. Rescher U., Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004, 117:2631-2639.
11. 2+-regulated association of lipid microdomains. J Cell Biol 2000, 150:1113-1123.
12. Hayes M.J., Moss S.E. Annexins and disease. Biochem Biophys Res Commun 2004, 322:1166-1170.
13. Zhang X., Liu S., Sun M.-Z., et al. The association of annexin A2 and cancers. Clin Transl Oncol 2012, 14:634-640.
14. Wu N., Liu S., Sun M.-Z., et al. The role of annexin A3 playing in cancers. Clin Transl Oncol 2013, 15(2):106-110.
15. Nakao H., Watanabe M., Maki M. A new function of calphobind I (annexin V). Eur J Biochem 1994, 223:901-908.
16. Schutters K., Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 2010, 15:1072-1082.
17. van Genderen H.O., Kenis H., Hofstra L., et al. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta 2008, 1783:953-963.
18. Huber R., Römisch J., Pâques E.P. The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membrane. EMBO J 1990, 9:3867-3874.
19. Gerke V., Moss S.E. Annexins: from structure to function. Physiol Rev 2002, 82:331-371.
20. Huber R., Berendes R., Burger A., et al. Annexin V-crystal structure and its implications on function. Behring Inst Mitt 1992, 91:107-125.
21. Huber R., Schneider M., May I., et al. The calcium binding sites in human annexin V by crystal structure analysis at 2.0Å resolution. Implications for membrane binding and calcium channel activity. FEBS Lett 1990, 275(1-2):15-21.
22. Olofsson A., Mallouh V., Brisson A. Two-dimensional structure of membrane-bound annexin V at 8Å resolution. J Struct Biol 1994, 113(3):199-205.
23. Lizarbe M.A., Barrasa J.I., Olmo N., et al. Annexin-phospholipid interactions. Functional implication. Int J Mol Sci 2013, 14:2652-2683.
24. Ohkubo T., Yamamoto J., Sugawara Y., et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000, 191:657-660.
25. Tang Z., Ye S., Liu Y., et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:187-196.
26. Cheng S., Wu M., Chen H., et al. Significance of typing tumor thrombi in determination of treatment and assessment of prognosis of hepatocellular carcinoma with tumor thrombi in the portal vein. Natl Med J China 2004, 84(1):3-5.
27. Guo W., Man X., Yuan H., et al. Proteomic analysis on portal vein tumor thrombus associated proteins for hepatocellular carcinoma. Natl Med J China 2007, 87(30):2094-2097.
28. Liu S., Sun M.-Z., Tang J., et al. High performance liquid chromatography/nano-electrospray ionization tandem mass spectrometry, two-dimensional difference in-gel electrophoresis and gene microarray identification of lymphatic metastasis-associated biomarker. Rapid Commun Mass Spectrom 2008, 22(20):3172-3178.
29. Sun M.-Z., Liu S., Tang J., et al. Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis. Proteomics 2009, 9(12):3285-3302.
30. Sun M.-Z., Liu S., Tang J. Proteomics investigation of mouse hepatocarcinoma cell lines with different lymph node metastasis capacities. Chem J Chin Univ 2009, 30(3):517-524.
31. Davies E.L. Breast cancer. Medicine 2012, 40(1):5-9.
32. Sato H., Ogata H., de Luca L.M. Annexin V inhibits the 12-O-tetradecanoylphorbol-13- acetate-induced activation of Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of Shc in MCF-7 cells. Oncogene 2000, 19:2904-2912.
33. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988, 334:661-665.
34. El-Shemerly M.Y., Besser D., Nagasawa M., et al. 12-O-tetradecanoylphorbol-13-acetate activates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of SOS involving serine phosphorylation of Shc in NIH3T3 cells. J Biol Chem 1997, 272:30599-30602.
35. Bae S.M., Lee C.H., Cho Y.L., et al. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol 2005, 99:26-35.
36. Karube A., Shidara Y., Hayasaka K., et al. Suppression of calphobindin I production in carcinoma of uterine cervix and endometrium. Gynecol Oncol 1995, 58:295-300.
37. Raynal P., Hullin F., Ragab-homas J.M., et al. Annexin 5 as a potential regulator of annexin 1 phosphorylation by protein kinas C. In vitro inhibition compared with quantitative data on annexin distribution in human endothelial cells. Biochem J 1993, 292:759-824.
38. Dubois T., Mira J.P., Feliers D., et al. Annexin V inhibits protein kinase C activity via a mechanism of phospholipid sequestration. Biochem J 1998, 330:1277-1282.
39. Jantová S., Cipák L., Cemáková M., et al. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 2003, 55:1143-1149.
40. Youn M.J., So H.S., Cho H.J., et al. Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull 2008, 31:789-795.
41. Lu B., Zhao J., Xu L., et al. Identification of molecular target proteins in berberine-treated cervix adenocarcinoma HeLa cells by proteomic and bioinformatic analyses. Phytother Res 2012, 26:646-656.
42. Watson A.J. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006, 57:107-121.
43. Kahi C.J., Rex D.K., Imperiale T.F. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 2008, 135:380-399.
44. Xue G., Hao L., Ding F., et al. Expression of annexin A5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas. J Clin Gastroenterol 2009, 43(9):831-837.
45. Wu X., Tang Y., Huang W., et al. Identification of proteins interacting with multidrug resistance protein in gastric cancer. World J Gastroenterol 2011, 19(35):3568-3573.
46. Wang J., Li J., Wang K. Advances in mechanisms of drug resistance in gastric cancer. World J Gastroenterol 2009, 17:2692-2699.
47. Tang S., Huang W., Zhong M., et al. Identification keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines. J Proteomics 2012, 75(8):2352-2360.
48. Fallica B., Makin G., Zaman M.H. Bioengineering approaches to study multidrug resistance in tumor cells. Integr Biol (Camb) 2011, 3:529-539.
49. Oshikata A., Matsushita T., Ueoka R. Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng 2011, 111:590-593.
50. Drain S., Catherwood M.A., Alexander H.D. Multidrug resistance in the chronic lymphoproliferative disorders. Leuk Lymphoma 2010, 51:1793-1804.
51. Castellini M.A., Buguliskis J.S., Casta L.J., et al. Malaria drug resistance is associated with defective DNA mismatch repair. Mol Biochem Parasitol 2011, 177:143-147.
52. Cui Y., Zhang D., Jia Q., et al. Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest 2009, 27:747-755.
53. Yassa N.A., Yang J., Stein S., et al. Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. J Clin Ultrasound 1997, 25:473-480.
54. Tyczynski J.E., Parkin D.M. Bladder cancer in Europe. ENCR cancer Fact Sheets 2003, 3:1-4.
55. Mitra A.P., Almal A.A., George B., et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 2006, 6(1):159-174.
56. 2+-dependent apoptosis. Proc Natl Acad Sci U S A 2002, 99:8054-8059.
57. Townson J.L., Naumov G.N., Chamber A.F. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003, 3:631-642.
58. Lee E.Y., Cho H., Kim C.W. Proteomic analysis of cancer stem cells in human prostate cancer cells. Biochem Biophys Res Commun 2011, 412:279-285.
59. Branchvogel B., Moch H., Pausch F., et al. Pericascular cells expressing annexin A5 define a novel mesenchymal stem cell-like population with the capacity to differentiate into multiple mesenchymal lineages. Development 2005, 132:2657-2668.
60. Dooley T.P., Reddy S.P., Wilborn T.W., et al. Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR. Biochem Biophys Res Commun 2003, 306:1026-1036.
61. Melle C., Ernst G., Schimmel B., et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics 2003, 2:443-452.
62. Wehder L., Arndt S., Murzik U., et al. Annexin A5 is involved in migration and invasion of oral carcinoma. Cell Cycle 2009, 8(10):1552-1558.
63. Rajcevic U., Petersen K., Knol J.C., et al. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics 2009, 8(11):2595-2612.
64. Hayashi E., Kuramitsu Y., Okada F., et al. Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005, 5:1024-1032.
65. Domont E.A., Reutelingsperger C.P., Heidendal G., et al. Bringing cell death alive. Cardiovasc Toxicol 2003, 3:207-218.
66. Mohiti J., Walker J.H., Caswell A.M. Studies on annexins in primary cultures of human osteoblasts and in the human osteosarcoma cell line MG-63. Biochem Soc Trans 1995, 23:36S.
67. Anastasios S., Susanne B., Ulf H., et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol 2012, 166:657-667.
68. Ward R., Lindsay S., Sheline G.E., et al. Tumors of the thyroid and parathyroid glands. Calif Med 1964, 101:462-469.